Abstract
The use of targeted viral vectors to localize gene transfer to specific cell types holds many advantages over conventional, non-targeted vectors currently used in gene therapy. The resulting improvements in gene localization from targeted adenovirus vectors are likely to reduce immunogenicity and toxicity, increase safety, and enable the systemic administration of these vectors for multiple indications including cancer, cardiovascular disease, and inflammatory disease. Recent advances in the biological understanding of adenovirus structure and adenovirus receptor interactions have fueled the rapid development of targeted adenovirus vectors. Two basic requirements are necessary to create a targeted adenovirus vector: interaction of adenovirus with its native receptors must be removed and novel, tissue-specific ligands must be added to the virus. Two general approaches have been used to achieve these basic requirements. In the ‘two-component’ approach, a bispecific molecule is complexed with the adenovirus. The bispecific component simultaneously blocks native receptor binding and redirects virus binding to a tissue-specific receptor. In the ‘one-component’ approach the adenovirus is genetically modified to ablate native receptor interactions and a novel ligand is genetically incorporated into one of the adenovirus coat proteins. Two-component systems offer great flexibility in rapidly validating the feasibility of targeting via a particular receptor. One-component systems offer the best advantages in producing a manufacturable therapeutic and in more completely ablating all native adenovirus receptor interactions. The coming challenges for targeted adenovirus vectors will be the demonstration that the technology performs in vivo. Ultimately, or in parallel, ‘receptor-targeting’ technology can be combined with improved adenovirus backbones and with ‘transcriptional targeting’ approaches to create adenovirus which deliver genes selectively, safely, and with little immune response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 1997 275: 1320–1323
Tomko RP, Xu R, Philipson L . HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses Proc Natl Acad Sci USA 1997 94: 3352–3356
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins avb3 and avb5 promote adenovirus internalization but not virus attachment Cell 1993 73: 309–319
Nemerow GR, Stewart PL . Role of αv integrins in adenovirus cell entry and gene delivery Microbiol Molec Biol Rev 1999 63: 725–734
Hong SS et al. Adenovirus type 5 fiber knob binds to MHC class I a2 domain at the surface of human epithelial and B lymphoblastoid cells EMBO J 1997 16: 2294–2306
Davison E, Kirby I, Elliott T, Santis G . The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber J Virol 1999 73: 4513–4517
Stewart PL, Fuller SD, Burnett RM . Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy EMBO J 1993 12: 2589–2599
Stewart PL et al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization EMBO J 1997 16: 1189–1198
Athappilly FK et al. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution J Mol Biol 1994 242: 430–455
Xia D, Henry LJ, Gerard RD, Deisenhofer J . Crystal Structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution Structure 1994 2: 1259–1270
Roelvink PR, Lee GM, Kovesdi I, Wickham TJ . Identification of a conserved receptor binding site on the fiber proteins of CAR recognizing adenoviridae Science 1999 286: 1568–1571
Douglas JT et al. Targeted gene delivery by tropism-modified adenoviral vectors Nat Biotech 1996 14: 1574–1578
Wickham TJ, Roelvink PW, Brough DE, Kovesdi I . Adenovirus targeted to heparin-containing receptors increases its gene delivery efficiency to multiple cell types Nat Biotech 1996 14: 1570–1573
Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins J Virol 1997 71: 8221–8229
Shinoura N et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas Cancer Res 1999 59: 3411–3416
Rajotte D et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display J Clin Invest 1998 102: 430–437
Einfeld DA et al. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base J Virol 1999 73: 9130–9136
Douglas JT et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities Nat Biotechnol 1999 17: 470–475
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wickham, T. Targeting adenovirus. Gene Ther 7, 110–114 (2000). https://doi.org/10.1038/sj.gt.3301115
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301115
Keywords
This article is cited by
-
Peptides as drug delivery vehicles across biological barriers
Journal of Pharmaceutical Investigation (2018)
-
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
Archives of Toxicology (2013)
-
Intramyocardial transplantation of fibroblasts expressing vascular endothelial growth factor attenuates cardiac dysfunction
Gene Therapy (2010)
-
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells
Cancer Gene Therapy (2010)
-
Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma
Journal of Experimental & Clinical Cancer Research (2009)